Latest Us Market News

Energy Transition Minerals (ETM) has appointed Ballard Partners as strategic advisors in the US, reinforcing its plan to list on the Nasdaq Stock Exchange and deepen its engagement with American stakeholders.

Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.

Nexsen Limited has initiated FDA engagement for its rapid Group B Streptococcus diagnostic sensor, aiming for expedited US market entry, while bolstering its leadership team and scientific credentials.

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Little Green Pharma welcomes a landmark US Executive Order directing cannabis rescheduling, a move poised to reshape the global medicinal cannabis landscape.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

Calix Limited has landed a significant three-year contract with a major US agriculture company, potentially adding up to A$10 million in annual revenue starting early 2026.

Orthocell has reached a significant milestone with 100 units of its nerve repair product Remplir™ sold in the US, signaling accelerating adoption in a $1.6 billion market. The company’s strategic medical education and distributor network are driving momentum ahead of further hospital approvals.

Proteomics International has secured a US patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma, marking a critical step toward commercialisation in the world’s largest healthcare market.

Talga Group has opened a $5 million Share Purchase Plan at $0.41 per share, offering shareholders free attaching and piggyback options to support its planned anode production ramp-up and US expansion.

ECS Botanics is strategically preparing for entry into the US medicinal cannabis market, leveraging its EU-GMP certification and proprietary genetics amid evolving regulatory landscapes.

Adherium Limited reports a remarkable 103% quarter-on-quarter growth in Remote Patient Monitoring subscription revenues for Q2 FY26, driven by strong device shipment momentum and strategic operational changes.